Cargando…
Commentary: Expedited Regulatory Review of Low-Value Drugs
Lexchin has criticized Health Canada's recently published draft guidance on accelerated drug review, expressing concern over agency conflicts of interest and observing that priority review and notice of compliance with conditions correlate poorly with therapeutic benefit. Although agency operat...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Longwoods Publishing
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294442/ https://www.ncbi.nlm.nih.gov/pubmed/32538347 http://dx.doi.org/10.12927/hcpol.2020.26226 |